Article
Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Dr. Angela Smith, of UNC Lineberger Comprehensive Cancer Center, regarding the significance of this approval for providers and patients. The interview took place on May 1, 2020. Dr. Smith serves on the study advisory committee for UroGen Pharma.
More from Urology Times®:
UTUC therapy yields high rate of disease eradication, durability
Blue light cystoscopy enables earlier detection of invasive bladder tumors
Further Evaluation of Tivozanib Shows Promise for Relapsed, Refractory Renal Cell Carcinoma
